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Abstract
Background—Ductal carcinoma in situ (DCIS) incidence has grown with the implementation of 
screening and its detection varies across International Cancer Screening Network (ICSN) 
countries. The aim of this survey is to describe the management of screen-detected DCIS in ICSN 
countries and to evaluate the potential for treatment related morbidity.
Methods—We sought screen-detected DCIS data from the ICSN countries identified during 
2004–2008. We adopted standardised data collection forms and analysis and explored DCIS 
diagnosis and treatment processes ranging from pre-operative diagnosis to type of surgery and 
radiotherapy.
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Results—Twelve countries contributed data from a total of 15 screening programmes, all from 
Europe except the United States of America and Japan. Among women aged 50–69 years, 
7,176,050 screening tests and 5324 screen-detected DCIS were reported. From 21% to 93% of 
DCIS had a pre-operative diagnosis (PO); 67–90% of DCIS received breast conservation surgery 
(BCS), and in 41–100% of the cases this was followed by radiotherapy; 6.4–59% received sentinel 
lymph node biopsy (SLNB) only and 0.8–49% axillary dissection (ALND) with 0.6% (range by 
programmes 0–8.1%) being node positive. Among BCS patients 35% received SLNB only and 
4.8% received ALND. Starting in 2006, PO and SLNB use increased while ALND remained 
stable. SLNB and ALND were associated with larger size and higher grade DCIS lesions.
Conclusions—Variation in DCIS management among screened women is wide and includes 
lymph node surgery beyond what is currently recommended. This indicates the presence of 
varying levels of overtreatment and the potential for its reduction.
Keywords
Breast cancer; Ductal carcinoma in situ (DCIS); Screening mammography; Overtreatment; 
Axillary staging; Cancer registration
1. Introduction
Ductal carcinoma in situ (DCIS) has become a relatively common disease after the 
introduction of screening mammography, representing up to 20–25% of all incident breast 
malignancies in industrialised countries [1–4]. The natural history of screen-detected DCIS 
is not yet completely understood [5] and we are therefore in large part unable to distinguish 
different conditions that are likely to exist under the same label of DCIS [6,7].
Management guidelines increasingly take this uncertainty into account by trying both to 
provide adequate care and to avoid unnecessary treatment. For example, axillary lymph 
node dissection (ALND) is not recommended for women with DCIS [8–10]. The 
International Cancer Screening Network (ICSN) oversees organised programmes that 
include quality monitoring of the process of screening and care. The purpose of the report is 
to assess practice variation in the management of screen-detected DCIS and the potential 
morbidity associated with detection of DCIS among participants in the ICSN.
2. Patients and methods
A survey was launched within the ICSN. All of the screening settings covered were 
population-based, organised screening programmes, with the exception of Czech Republic, 
which at the time did not adopt personal invitations, and of the United States, whose data, 
provided by the Breast Cancer Surveillance Consortium, derived from opportunistic 
screening in well defined populations.
Selected characteristics of participating programmes were collated from the ICSN web site 
(http://appliedresearch.cancer.gov/icsn) and reported in Table 1. Attendance rates exceeded 
60% in all programmes for which this information was available with the exceptions of 
Switzerland and Japan.
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A previous paper [4] on DCIS detection reports in detail the design of this survey. In brief, 
we sought data from the 33 ICSN member countries regarding the pure DCIS cases they 
identified within their screened population between January 1, 2004 and December 31, 
2008. We asked sites to complete, based on individual data records from their screening and 
clinical databases often obtained by linkage with population-based cancer registries, a 
structured questionnaire that summarised data on DCIS detection, diagnosis and treatment. 
The questionnaire was piloted in a regional screening programme before distribution. 
Internal data consistency was checked routinely and outlying data were verified with data 
providers. All data were stratified by calendar year and age in decades, both referred to the 
date of the screening test. The following data stratifications were also included in the 
questionnaire: type of breast surgery by DCIS size; nodal surgery by DCIS size; nodal 
surgery by nuclear grade; nodal surgery by type of breast surgery; and radiotherapy by type 
of breast surgery. As size by clinical imaging was often unavailable, all sites were asked to 
provide pathological size (≤10 mm, 11–20 mm, >20 mm).
For the analysis of DCIS management process we selected a number of measures 
encompassing issues ranging from diagnosis to surgical and adjuvant treatment, namely: 
pre-operative diagnosis (PO); time from abnormal screen to surgery; use of breast 
conserving surgery (BCS) as definitive intervention; use of ALND and sentinel lymph nodes 
biopsy (SLNB); radiotherapy after BCS. Indicators were identified, following a systematic 
literature review, from two main sources [9,10], by selecting measures believed to be 
collectable retrospectively from participating screening programmes. A pre-operative 
diagnosis was defined as the presence prior to open surgery of a definitive diagnosis of 
malignancy based on either fine needle aspiration cytology (FNAB) or core biopsy. Waiting 
time applied to patients with surgery as first treatment only. SLNB rates refer to patients 
who received this procedure as the only axillary procedure.
For all parameters, project documentation instructed sites to indicate the number of missing 
values. All analyses reported in this paper were restricted to ages 50–69, as this was the age 
range covered by most participating programmes, and in order to minimise confounding by 
age. As not all programmes were able to provide data for the entire time period, time trend 
analysis was restricted to the years 2004–2007.
All files provided by participating centres were included in a flat file and the resulting 
database analysed by using the R environment (v. 3.0.0). All measures were expressed as 
proportions, where the numerator was the number of cases managed as described in the 
measure definition and the denominator the number of eligible cases, after subtraction of 
missing values. The χ2 test was used for studying differences between pairs of parameters or 
trends.
3. Results
Screening co-ordination centres in 12 countries volunteered to participate and contributed 
data from a total of 15 screening programmes, all from Europe except United States of 
America (USA) and Japan. Denmark and Spain provided separate regional data. In the age 
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group 50–69 years 7,176,050 screening tests and 5324 screen-detected DCIS were reported, 
ranging from 48 from Luxembourg to 1066 from Italy (Table 1).
Results of process of care measures are illustrated in Table 2. Not all programmes were able 
to provide information for all items. In total, a pre-operative diagnosis was reported for 73% 
of the DCIS cases ranging from 21% to 93% across areas, surgical-waiting-time-within-60-
days was 47% ranging from 25% to 85%, BCS was performed for 78% of cases ranging 
from 67% to 90%, radiotherapy (RT) after BCS for 66% of cases ranging from 41% to 
100%, ALND for 7.9% ranging from 0.8% to 49%, and SLNB (with no ALND) for 35% 
ranging from 6.4% to 59%. Any nodal surgery was performed for 43% of all DCIS, ranging 
from 19% in The Netherlands to 63% in Ireland. Most centres reported to use more 
frequently SLNB only than ALND, with the exceptions of Japan, Luxembourg and the USA 
(Table 2).
Results for each indicator stratified by time period are shown in Table 3. Use of pre-
operative diagnosis and SLNB increased over time. There was a slight decrease in the 
proportion of DCIS cases operated within 60 days of diagnosis.
Both ALND and SLNB were more frequent at mastectomy (Table 4) and in high grade and 
larger tumours (Table 4 and Figs. 1, 2). ALND and SLNB were performed in about 20% and 
more than 50% of mastectomies, respectively, and in 5% and 35% of BCS. Their usage 
approximately doubles from low to high nuclear grade and from small (≤10 mm) to large 
(>20 mm) pathological size. Of cases with any type of nodal surgery (1980/4607or 43%), 
only 0.6% were node positive (range by programmes 0–8.1%, Table 2).
4. Discussion
We evaluated six measures of DCIS management across 15 active screening programmes in 
Europe, Japan and the USA. As reported by us elsewhere [4], age-standardised detection 
rates of DCIS varied from 0.41 to 1.38/1000 women. In this report we observed that pre-
operative evaluation, surgical wait times, use of nodal surgery, and radiation therapy also 
varied substantially across programmes. The implications are that women with potentially 
detectable DCIS may experience very different morbidity depending upon where they are 
screened and seek care because both their likelihood of a diagnosis and how it is treated vary 
across countries. Despite this wide variation, practices overall seem to be moving towards 
the consensus recommendations on DCIS treatment except SLNB has increased over time 
also in low and intermediate grade and small DCIS treated with BCS.
Cytological or histological pre-operative diagnosis is recommended in order to limit the 
need for open surgical biopsies, to allow for surgical planning, and to avoid under or 
overtreatment. Our overall result of 73% (Table 2), though slightly increasing over time 
(Table 3), is short of the target of 90% suggested by some guidelines [9,10] and the range 
among programmes is very wide, with only two Spanish programmes coming close to or 
above the stated standard. Even though FNAB and core biopsy are both accepted modalities 
for preoperative diagnosis, the latter allows discriminating invasive from in situ lesions and, 
in most settings, it is likely to provide a higher proportion of preoperative diagnosis being 
more sensitive and specific [11]. However, this distinction is not available in our data. 
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Centres with low level of preoperative diagnosis reported that, at the time under study, cases 
received exclusively or predominantly FNAB.
Women also face a wide variation in the range of waiting times for the definitive operation. 
Although it is recognised that two or three months delay from screening to treatment is not 
likely to affect prognosis (especially in the case of slowly growing lesions such as most 
DCIS), relatively long waiting times may cause anxiety and affect quality of life [12].
Using BCS for the surgical treatment of DCIS is usually considered good practice, even if it 
is recognised that patient preference plays a role [13]. The proportion of BCS in our series is 
high (78% overall) and relatively constant across programmes and time periods, with only 
one programme reporting slightly short of 70% and with three programmes exceeding 85%. 
BCS for DCIS not greater than 2 cm in pathological size is even more frequent (88% in 
2190 cases of this size). In England, where a report on non-invasive breast cancers 
diagnosed within and outside the national breast cancer screening programme is periodically 
issued, the proportion of BCS in screen-detected cases in 2006–2007 is 71% [14], while 
70% is the figure reported by a French survey for the period 2003–2004 [15]. Even lower 
was the proportion of BCS in the East Netherlands during 1999–2003: 55% [16]. In a 
population-based study in Southern Netherlands, which documented an increasing time 
trend, it was reported to be 68% in 2010 [17].
BCS is often complemented by radiotherapy [8,18], in order to lower the risk of local in situ 
or invasive recurrence. In our series radiotherapy is performed in 66% of BCS patients, with 
the lowest result being 41%. In United Kingdom during 2003–2006 53% of BCS received 
radiotherapy, with radiotherapy provision significantly related to tumour size and grade [14]. 
In France in 2003–2004 the corresponding figure was 89% [15]. In the East Netherlands 
during 1999–2003 [16] and in the Southern part of the country in 2010 [17] radiotherapy 
was performed respectively in 34% and in 89% of DCIS treated with BCS.
Management of the axilla is a subject of debate in DCIS, but there is consensus regarding 
the need to avoid ALND, considered unnecessary and a cause of frequent complications [8–
10]. This survey documented that ALND takes place in 5% of women with DCIS as final 
diagnosis treated by BCS and in almost 20% of women treated by mastectomy. The use of 
SLNB was much more frequent and on the rise over time, with a large variation among 
programmes, so that in our series almost half of all cases had any type of nodal surgery. We 
were able to show that the recommendation [8,9,19–21] to limit SLNB to women 
undergoing mastectomies and/or those with large (where micro-invasion might be more 
easily overlooked) or high grade DCIS were clearly reflected in actual practice, although not 
fully followed since we observed one third of BCS patients and many small or low grade 
DCIS had SLNB only (Table 4 and Figs. 1, 2). Notably, the proportion of all DCIS cases 
associated with positive lymph nodes in this study was low (0.6%) and thus not likely to be 
influencing treatment management. These results add support to the limited value of nodal 
staging in women with screen-detected DCIS [22,23] and to recent guidelines [24] that 
further restrict the indication for SLNB in DCIS, suggesting that clinicians consider SLNB 
when mastectomy is planned, in case of clinically evident mass lesions suggestive of 
invasive cancer, and in very large size DCIS (>5 cm.) only.
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Similarly to our observation, the correlation of the use of SLNB with DCIS size and grade 
has been reported in an analysis of US Seer data 1998–2002 [25], in France during 2003–
2004 [15] and in Australia during 1995–2000 [26]. However, in Australia the use of nodal 
surgery was correlated with the size of the breast lesion but not with its grade.
In England in 2006–2007 the use of SLNB in screen-detected non-invasive breast cancers 
having breast conserving surgery was 4.0% [14], a figure lower than in any of the 
programmes included in our survey. In France in 2003–2004 SLNB was performed in 21% 
of patients and the proportion of ALND was 10% [15]. In the East Netherlands during 
1999–2003 any axillary staging procedure was performed in 25% of DCIS [16] while in 
Southern Netherlands use of SLNB was reported being 65% in 2010 [17]. In Italy the use of 
SLNB in screen-detected DCIS increased from 20% to slightly over 50% from 2001 to 2007 
and then remained virtually stable through 2010 [27].
Limitations of this study are those specific to aggregate data surveys: limited detail in 
available data, possible use of different definitions of study parameters in the different sites, 
need to restrict overall data analyses to data stratifications being planned in advance. Not all 
programmes could contribute all required data and the number of missing values for some of 
the parameters was high. However, we minimised these limitations by providing strictly 
structured data collection forms, with several prespecified stratification tables, detailed 
documentation on definitions used, and internal consistency checks. It must be also 
acknowledged that this paper provides a picture of DCIS management during 2004–2008, 
and practice is likely to have evolved since then, both in detection, with the gradual 
introduction of digital mammography [4], and in treatment. ICSN will consider updating 
these results seeking data from an even larger number of programmes.
This survey covered screen-detected DCIS cases only. Few countries have yet similar 
information available from the in situ carcinoma diagnosed at all ages outside organised 
screening programmes, which have been quantified as 51% of all cases in Southern 
Netherlands [17], 43% in Finland [28], and 38% in United Kingdom [14]. Projects 
conducted in co-operation between clinical Centres and population Cancer Registries [17] 
could cover this gap.
This study is, to our knowledge, the first large (more than 5000 cases) international survey 
of DCIS management practices. We found wide variation in clinical management for all of 
the parameters studied. While awaiting progress from research enabling to differentiate 
indolent lesions amenable of follow up only from those at high risk of subsequent invasive 
cancer [29–31], efforts should be made to optimise diagnostic assessment and management 
of screen-detected cases to mitigate overdiagnosis and overtreatment [32]. Specifically, we 
found that axillary surgery, although used more often in high grade and large size lesions, 
showed an increasing time trend and was performed, with large variation between centres, 
beyond what is recommended by guidelines. This indicates the presence of varying levels of 
overtreatment and the potential for the reduction of treatment-related morbidity. In fact, 
although less frequently harmful than ALND, SLNB is not exempt from complications. 
According to the update of the SLNB American Society of Clinical Oncology Clinical 
Practice Guidelines [24], which includes a literature review of adverse events, important 
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morbidity of node surgery includes lymphoedema, infections, seroma and neurologic 
complications. These were found to be more frequent in patients receiving ALND as 
opposed to SLNB only, but they are still not negligible even in the latter. For example, in the 
ALMANAC trial [33] at 12 months after operation lymphoedema occurred in 5% of patients 
having received SLNB only versus 13% of patients having received ALND, and sensory 
loss 11% and 31% respectively.
Specialised multidisciplinary care for breast cancer has proved to improve process of care 
[34] and decrease mortality [35]. Screening programmes should link to specialised clinical 
Units and Cancer Registries and jointly set up or expand multidisciplinary teams in charge 
of quality assurance of diagnosis and treatment of screen-detected lesions, including DCIS, 
so to assure that current guidelines are applied and opportunities for research in the 
heterogeneity of these lesions are taken.
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Fig. 1. 
Ductal carcinoma in situ: performance of sentinel lymph node biopsy (SLNB) only by 
pathological size and time period (a), and by nuclear grade and time period (b). Any type of 
breast surgery included. Cases reported for year 2008 and countries not reporting cases for 
the whole period 2004–2007 or lacking the stratification by size and grade were excluded 
from this analysis. Data are included for Finland, Ireland, Norway, Spain, Switzerland and 
United States of America (USA).
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Fig. 2. 
Ductal carcinoma in situ: axillary lymph node dissection (ALND) by pathological size and 
time period (a), and by nuclear grade and time period (b). Any type of breast surgery 
included. Cases reported for year 2008 and countries not reporting cases for the whole 
period 2004–2007 or lacking the stratification by size and grade were excluded from this 
analysis. Data are included for Finland, Ireland, Norway, Spain, Switzerland and United 
States of America (USA).
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